◆英語タイトル:Pharmascience Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013222
◆発行会社(調査会社):
GlobalData
◆発行日:2017年11月28日
◆ページ数:40
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Pharmascience Inc (Pharmascience) is a pharmaceutical company that develops, manufactures and markets medicinal products. The company offers generic, prescription, over-the-counter and private label OTC products. It offers drugs in therapeutic areas of anti-inflammatory, cancer, cardiovascular, pain management, allergies, anti-infectives, gastro-intestinal, cough and cold, and others. It offers products to healthcare institutions, drug store retail chains, and others. The company offers products in the form of capsules, creams, liquids, injectables, patches and others. It operates research, development and production facilities in Montreal. The company markets its products across Canada. Pharmascience is headquartered in Montreal, Quebec, Canada.
Pharmascience Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Pharmascience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Pharmascience Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Pharmascience Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Pharmascience Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Pharmascience Inc, Medical Devices Deals, 2011 to YTD 2017 9
Pharmascience Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Pharmascience Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Helix BioPharma Completes Sale Of Rivex Pharma To Pharmascience For US$8.6 Million 12
Venture Financing 14
RDD Pharma Raises USD9.5 Million in Series B Financing 14
Edesa Biotech Raises USD5.7 Million in Series A Financing 15
Pharmaceutics International Raises USD93 Million in Venture Financing 16
Bionpharma Secures USD8.73 Million in Venture Funding 18
Bion Pharma Raises USD21 Million in Venture Financing 19
Partnerships 20
PendoPharm Enters into Distribution Agreement with Tillotts Pharma 20
Anika Therapeutics Enters into Agreement with PendoPharm 21
Pendopharm Enters into Distribution Agreement with Sanofi-aventis Canada 22
Pharmascience Enters Into Co-Development Agreement With University Of Montreal 23
Pharmascience Enters Into Joint Venture With Korea Kolmar To Form Pharmascience Korea 24
Licensing Agreements 25
Pendopharm Enters into Licensing Agreement with Edesa Biotech 25
Sigmoid Pharma Enters into Licensing Agreement with PendoPharm for CyCol 26
Paion Exercises Option for Licensing Agreement with PendoPharm for Remimazolam 27
Redx Pharma Enters Into Licensing Agreement With Pharmascience For Cancer Program 28
DARA BioSciences Enters Into Licensing Agreement With Uman Pharma For Gemcitabine 29
Equity Offering 30
Sigmoid Pharma Raises USD6.3 Million in Private Placement 30
Acquisition 31
Pharmascience Acquires 10.4% Stake In Bellus Health For US$17.4 Million 31
CFR Pharma Acquires 50.79% Stake In Uman Pharma For US$26.5 Million 33
Pharmascience Acquires Aegera Therapeutics 34
Pharmascience Inc – Key Competitors 35
Pharmascience Inc – Key Employees 36
Pharmascience Inc – Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Recent Developments 39
Corporate Communications 39
Oct 13, 2016: Pharmascience Announces Important Restructuring 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40
List of Tables
Pharmascience Inc, Pharmaceuticals & Healthcare, Key Facts 2
Pharmascience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Pharmascience Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Pharmascience Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Pharmascience Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Pharmascience Inc, Medical Devices Deals, 2011 to YTD 2017 9
Pharmascience Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Helix BioPharma Completes Sale Of Rivex Pharma To Pharmascience For US$8.6 Million 12
RDD Pharma Raises USD9.5 Million in Series B Financing 14
Edesa Biotech Raises USD5.7 Million in Series A Financing 15
Pharmaceutics International Raises USD93 Million in Venture Financing 16
Bionpharma Secures USD8.73 Million in Venture Funding 18
Bion Pharma Raises USD21 Million in Venture Financing 19
PendoPharm Enters into Distribution Agreement with Tillotts Pharma 20
Anika Therapeutics Enters into Agreement with PendoPharm 21
Pendopharm Enters into Distribution Agreement with Sanofi-aventis Canada 22
Pharmascience Enters Into Co-Development Agreement With University Of Montreal 23
Pharmascience Enters Into Joint Venture With Korea Kolmar To Form Pharmascience Korea 24
Pendopharm Enters into Licensing Agreement with Edesa Biotech 25
Sigmoid Pharma Enters into Licensing Agreement with PendoPharm for CyCol 26
Paion Exercises Option for Licensing Agreement with PendoPharm for Remimazolam 27
Redx Pharma Enters Into Licensing Agreement With Pharmascience For Cancer Program 28
DARA BioSciences Enters Into Licensing Agreement With Uman Pharma For Gemcitabine 29
Sigmoid Pharma Raises USD6.3 Million in Private Placement 30
Pharmascience Acquires 10.4% Stake In Bellus Health For US$17.4 Million 31
CFR Pharma Acquires 50.79% Stake In Uman Pharma For US$26.5 Million 33
Pharmascience Acquires Aegera Therapeutics 34
Pharmascience Inc, Key Competitors 35
Pharmascience Inc, Key Employees 36
Pharmascience Inc, Other Locations 37
Pharmascience Inc, Subsidiaries 37